Viemed Healthcare, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-01. 2 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 6.4% | 2,540,114 | SCHEDULE 13G, 2025-07-15 | 2025-06-30 |
| Michael Moore | 5.9% | 2,294,018 | SCHEDULE 13D/A, 2026-09-24 | 2026-09-24 |
| Forager Capital Management, LLC | 4.9% | 1,886,872 | SCHEDULE 13G/A, 2026-07-24 | 2026-06-30 |
Purpose of Transaction (Item 4)
Michael Moore
Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: Each of the Reporting Persons holds the Common Shares as reported herein for investment purposes and does not have any specific plans or proposals regarding the Issuer in such Reporting Person's capacity as a holder of Common Shares. Except as set forth below, each of the Reporting Persons does not have any current plans or proposals which relate to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D. On September 24, 2026, MF LLC entered into a trading plan with Morgan Stanley Smith Barney LLC (the "Trading Plan") intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Pursuant to the Trading Plan, Morgan Stanley Smith Barney LLC may sell up to 246,000 Common Shares of the Issuer held by MF LLC during the period beginning on the Selling Start Date, as determined under the Trading Plan, which will be no earlier than December 24, 2026, and ending November 30, 2027, subject to predetermined trading conditions established under the Trading Plan. The Trading Plan was adopted at a time when neither Moore nor MF LLC was aware of any material non-public information regarding the Issuer. A copy of the Trading Plan is filed as Exhibit 99.2 to this Amendment No. 3 and is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2026-09-24
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-01 | Forager Capital Management, LLC | 5.5% | SCHEDULE 13G |
| 2025-07-15 | BlackRock Portfolio Management LLC | 6.4% | SCHEDULE 13G |
| 2025-11-07 | Forager Capital Management, LLC | 7.2% | SCHEDULE 13G/A |
| 2026-07-24 | Forager Capital Management, LLC | 4.9% | SCHEDULE 13G/A |
| 2026-09-24 | Michael Moore | 5.9% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Viemed Healthcare, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.